Kyverna Therapeutics Aktie News

EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P.

Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 202...

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.

Kyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications. Company achieved a 46% average improvement in SPS patients in phase 2 KYSA-8 study, surpassing clinical benchmarks of 20% improvement, and plans a BLA filing for SPS in 1H 2026. Phase 3 portion enrollment of phase 2/3 KYSA-6 registrational study for miv-cel in Myastheni...

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day o...

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events. A BLA submission for SPS is targeted for 1H26, with FDA approval prospects strengthened ...

Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarket trading.